CXCR4 and neoplasm: Moreover, inhibition of the CXCL12/CXCR4 signaling axis with AMD3100 (a CXCL12/CXCR4 antagonist) weakened the tumor’s mesenchymal signature in the SVZ and increased the tumor’s sensitivity to radiotherapy [19].